Krystal Biotech Inc (KRYS)

Return on equity (ROE)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	89,159	52,372	105,939	57,161	10,932	-29,812	-140,409	-135,307	-139,975	-129,729	-115,468	-103,723	-69,570	-58,147	-52,168	-42,638	-32,167	-27,141	-21,803	-20,318
Total stockholders’ equity	US$ in thousands	946,380	885,846	838,893	799,242	778,641	755,948	653,114	489,566	522,231	540,772	559,181	548,554	593,576	408,237	418,540	430,652	292,084	301,720	309,696	198,369
ROE		9.42%	5.91%	12.63%	7.15%	1.40%	-3.94%	-21.50%	-27.64%	-26.80%	-23.99%	-20.65%	-18.91%	-11.72%	-14.24%	-12.46%	-9.90%	-11.01%	-9.00%	-7.04%	-10.24%

December 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $89,159K ÷ $946,380K
= 9.42%

The Return on Equity (ROE) for Krystal Biotech Inc has shown a fluctuating trend over the past few years. The company experienced negative ROE values ranging from -10.24% to -27.64% during the period from March 2020 to June 2023. This indicates that the company was not efficiently utilizing shareholders' equity to generate profits during this period.

However, from September 2023 onwards, the ROE started to improve, with positive values of 1.40% in December 2023, reaching 9.42% by December 2024. This turnaround suggests that Krystal Biotech Inc has been more successful in using equity capital to generate profits for shareholders in recent quarters.

Overall, the improvement in ROE from negative to positive values indicates a positive shift in the company's profitability and efficiency in utilizing shareholders' equity. Further monitoring and analysis of ROE will be essential to assess the company's ongoing financial performance and effectiveness in generating returns for its shareholders.